+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biopharmaceutical Excipients Market - Global Forecast 2026-2032- Product Image
Biopharmaceutical Excipients Market - Global Forecast 2026-2032- Product Image
Sale

Biopharmaceutical Excipients Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5337416
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biopharmaceutical Excipients Market is projected to reach USD 4.25 Billion in 2026. It is expected to continue growing at a CAGR of 10.17%, reaching USD 7.72 Billion by 2032.

Biopharmaceutical excipients are no longer viewed as inactive ingredients; they are strategic formulation enablers that help protect proteins, peptides, antibodies, vaccines, cell therapies, and nucleic-acid-based medicines from aggregation, oxidation, denaturation, freeze-thaw stress, and delivery-system incompatibility. Demand is supported by the continued expansion of biologics pipelines, biosimilar launches, parenteral drug development, and patient-centric dosage formats that require high-purity sugars, amino acids, buffers, surfactants, polymers, salts, and tonicity agents.

The market is shaped by stringent pharmacopeial standards, supplier qualification expectations, and quality-by-design principles outlined across FDA, EMA, ICH, USP-NF, and Ph. Eur. frameworks. For industry leaders, competitive advantage depends on excipient performance data, low bioburden and endotoxin control, traceable sourcing, validated manufacturing, and robust documentation that can withstand regulatory scrutiny across global filings.

Transformative Shifts in the Excipients Landscape

The biopharmaceutical excipients landscape is shifting from commodity procurement toward performance-led, risk-managed formulation strategy. Biologics are inherently sensitive to temperature, pH, shear, interfacial stress, and impurities; therefore, excipient selection increasingly begins in early development rather than late-stage scale-up. Formulators are prioritizing excipients with well-characterized critical material attributes, multi-compendial compliance, and proven suitability for injectable and high-concentration biologic formulations.

Transformative shifts include the rise of subcutaneous biologics, prefilled syringes, autoinjectors, lyophilized products, lipid nanoparticle systems, and continuous manufacturing. These changes are increasing demand for excipients that improve viscosity management, protein stability, reconstitution performance, container-closure compatibility, and long-term shelf-life. Supply resilience has also become central as companies qualify secondary suppliers, regionalize sourcing, and strengthen excipient change-control governance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across biopharmaceutical excipient discovery, formulation design, process optimization, and quality monitoring. Machine learning models can analyze historical formulation datasets, stability results, molecular descriptors, and stress-condition outcomes to identify excipient combinations that reduce aggregation, improve solubility, and accelerate candidate screening. This supports faster design-of-experiments planning while reducing material use and laboratory cycles.

AI also improves supply and compliance intelligence by detecting quality trends, predicting batch variability, and supporting risk-based supplier monitoring. In regulated environments, AI must be paired with validated data governance, explainable models, audit trails, and human scientific review. Companies that integrate AI with QbD, PAT, electronic lab notebooks, and regulatory knowledge management are positioned to shorten development timelines without compromising product safety or data integrity.

Key Regional Insights Across Global Markets

Asia-Pacific is becoming a major growth engine for biopharmaceutical excipients as China, India, Japan, South Korea, Australia, and ASEAN countries expand biologics manufacturing, biosimilar development, vaccine capacity, and contract development and manufacturing services. Regional demand is strongest for injectable-grade buffers, stabilizers, surfactants, amino acids, sugars, and cryoprotectants that meet global pharmacopeial and regulatory expectations. Japan and South Korea emphasize advanced biologics quality systems, while China and India combine scale, policy support, and expanding domestic biopharma pipelines.

North America remains a leading innovation and regulatory benchmark region, anchored by the United States and Canada. The region benefits from mature biologics R&D, advanced fill-finish capacity, strong biotech activity, and high adoption of specialty excipients for monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Europe is similarly advanced, supported by Germany, France, Italy, Spain, the United Kingdom, and EU-level pharmaceutical quality frameworks that emphasize traceability, pharmacopoeial compliance, data integrity, and sustainability.

Latin America, led by Brazil and Mexico, is strengthening local biologics access and biosimilar adoption, creating opportunities for compliant excipient suppliers that can support technology transfer and reliable import logistics. The Middle East, particularly GCC markets, is investing in pharmaceutical localization and cold-chain infrastructure, while Africa is gradually building vaccine and biologics capacity through regional health security initiatives. Across these emerging regions, supplier education, documentation readiness, validated distribution, and temperature-controlled logistics remain decisive success factors.

Key Group Insights for Strategic Market Positioning

ASEAN is gaining relevance as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines expand pharmaceutical manufacturing capabilities and attract biopharma investment. The region’s need for high-quality biopharmaceutical excipients is closely tied to technology transfer, regulatory harmonization, and reliable cold-chain systems. Companies that provide technical documentation, formulation support, and multi-country compliance assistance can improve adoption across ASEAN markets.

The GCC is prioritizing healthcare self-sufficiency, pharmaceutical localization, and advanced hospital infrastructure, making it an increasingly attractive destination for excipients used in injectables, vaccines, and specialty biologics. The European Union remains a high-standard market where excipient suppliers must align with rigorous GMP expectations, REACH considerations where applicable, compendial quality, pharmacovigilance-linked quality practices, and transparent change notification processes.

BRICS economies are central to volume growth because Brazil, Russia, India, China, and South Africa combine large patient populations with expanding biologics access and domestic manufacturing strategies. G7 countries continue to lead in innovation, quality benchmarking, advanced therapy development, and high-value biologic launches, while NATO member markets overlap significantly with advanced pharmaceutical supply networks and emphasize secure, resilient supply chains for critical medicines, biologics, and vaccine preparedness.

Key Country Insights Shaping Demand

The United States is a critical strategic market for high-performance biopharmaceutical excipients because of its deep biologics pipeline, FDA-regulated manufacturing base, strong CDMO ecosystem, and advanced use of prefilled syringes, autoinjectors, and specialty injectable formulations. Canada complements this with growing biologics research, vaccine investment, and quality-focused procurement. Mexico and Brazil are important access markets in Latin America, where biosimilar adoption, public health purchasing, and local manufacturing initiatives are increasing the need for compliant excipient supply.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong demand for excipients backed by pharmacopeial compliance, regulatory documentation, and technical service. Germany and France are particularly important for biologics manufacturing, analytical quality systems, and specialty chemical expertise, while the United Kingdom supports advanced therapy innovation and clinical research. Russia remains a market where localization policies, import controls, and supply security influence purchasing decisions.

China and India are pivotal for scale, biosimilar development, vaccine production, and cost-competitive manufacturing, but global suppliers must address evolving regulatory requirements and expectations for consistent quality. Japan and South Korea are premium markets for biologics, biosimilars, and advanced formulation technologies, with strong emphasis on reliability, documentation, and precision manufacturing. Australia provides a quality-driven market for clinical development, specialized biologics research, and regional supply integration.

Actionable Recommendations for Industry Leaders

Industry leaders should treat excipient strategy as a core element of biologics development rather than a late-stage sourcing task. Early compatibility studies, stress testing, container-closure assessments, and stability modeling help reduce reformulation risk and support stronger regulatory submissions. Suppliers should invest in injectable-grade portfolios, low-endotoxin manufacturing, multi-compendial testing, extractables and leachables support, and digital documentation portals that simplify customer audits.

Executives should also build dual-sourcing strategies, formal change-control agreements, regional inventory models, and quality-risk management plans for critical excipients. Partnerships with CDMOs, analytical laboratories, and formulation technology providers can accelerate adoption. To improve visibility and commercial conversion, market participants should publish evidence-based technical content around protein stabilization, biosimilar formulation, lyophilization excipients, surfactant alternatives, lipid nanoparticle formulation, and regulatory-grade excipient qualification.

Research Methodology and Evidence Base

This executive summary is developed using a secondary-research-led methodology aligned with recognized standards for market intelligence. The analysis synthesizes public regulatory guidance, pharmacopeial references, peer-reviewed scientific literature, product documentation, patent activity, clinical development trends, and trade-level insights from reputable sources. Emphasis is placed on verifiable signals rather than speculative market sizing.

The research framework evaluates demand drivers, technology shifts, regional dynamics, regulatory requirements, and competitive positioning across the biopharmaceutical excipients value chain. Findings are validated through triangulation of source credibility, cross-regional consistency, and alignment with recognized quality frameworks such as ICH Q8-Q12, GMP expectations, USP-NF, Ph. Eur., and excipient supplier qualification practices.

Conclusion: Strategic Outlook for Biopharmaceutical Excipients

The biopharmaceutical excipients market is entering a performance-driven phase defined by biologics complexity, regulatory rigor, supply-chain resilience, and data-enabled formulation science. Excipients that can demonstrate consistent quality, strong functionality, and compatibility with advanced delivery systems will remain essential to next-generation biologics development.

Companies that combine scientific credibility, global compliance, AI-supported formulation intelligence, and dependable supply infrastructure will be best positioned to capture growth. As biologics, biosimilars, vaccines, and advanced therapies expand worldwide, excipient innovation will continue to influence product stability, manufacturability, patient experience, and commercial success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Biopharmaceutical Excipients Market, by Product
7.1. Introduction
7.2. Binders
7.2.1. Cellulosic Binders
7.2.2. Hydroxypropyl Methylcellulose
7.2.3. Polyvinylpyrrolidone
7.2.4. Starch & Modified Starches
7.3. Coatings
7.3.1. Controlled Release Coatings
7.3.2. Enteric Coatings
7.3.3. Film Coatings
7.3.4. Seal Coatings
7.3.5. Sugar Coatings
7.4. Diluents
7.4.1. Calcium Phosphates
7.4.2. Lactose
7.4.3. Microcrystalline Cellulose
7.5. Disintegrants
7.6. Lubricants & Glidants
7.7. Polyols
7.7.1. Mannitol
7.7.2. Sorbitol
7.8. Preservatives
7.9. Solubilizers & Surfactants/Emulsifiers
7.9.1. Esters
7.9.2. Polysorbates
7.9.3. Triglycerides
7.10. Suspending & Viscosity Agents
8. Biopharmaceutical Excipients Market, by Source
8.1. Introduction
8.2. Natural Excipients
8.3. Synthetic Excipients
9. Biopharmaceutical Excipients Market, by Formulation Type
9.1. Introduction
9.2. Injectable Formulations
9.2.1. Intramuscular
9.2.2. Intravenous
9.2.3. Subcutaneous
9.3. Oral Formulations
9.3.1. Capsules
9.3.2. Powders
9.3.3. Tablets
9.4. Topical Formulations
9.4.1. Creams
9.4.2. Gels & Ointments
9.4.3. Lotions
10. Biopharmaceutical Excipients Market, by End User
10.1. Introduction
10.2. Biopharmaceutical & Pharmaceutical Companies
10.3. Contract Manufacturers
10.4. Research Institutes
11. Biopharmaceutical Excipients Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. Biopharmaceutical Excipients Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Biopharmaceutical Excipients Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. ABITEC Corporation
15.2. Actylis
15.3. Asahi Kasei Corporation
15.4. Ashland Inc.
15.5. Avantor, Inc.
15.6. BASF SE
15.7. Clariant International Ltd.
15.8. Colorcon Ltd.
15.9. Croda International PLC
15.10. DFE Pharma GmbH & Co KG
15.11. Eastman Chemical Company
15.12. Evonik Industries AG
15.13. Fuji Chemical Industries Co., Ltd.
15.14. IMCD N.V.
15.15. Innophos Holdings, Inc.
15.16. International Flavors & Fragrances Inc.
15.17. JRS PHARMA GmbH + Co. KG
15.18. Kerry Group PLC
15.19. Meggle Group GmbH
15.20. Merck KGaA
15.21. Mitsubishi Chemical Group Corporation
15.22. NOF Corporation
15.23. Novo Nordisk A/S
15.24. Pfanstiehl, Inc.
15.25. Roquette Frères S.A.
15.26. Shin-Etsu Chemical Co., Ltd.
15.27. Sigachi Industries Limited
15.28. Spectrum Laboratory Products, Inc.
15.29. SPI Pharma, Inc. By Associated British Foods
15.30. The Archer-Daniels-Midland Company
15.31. The Dow Chemical Company
15.32. The Lubrizol Corporation
15.33. Wacker Chemie AG
List of Figures
FIGURE 1. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BINDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BINDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BINDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CELLULOSIC BINDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CELLULOSIC BINDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CELLULOSIC BINDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL HYDROXYPROPYL METHYLCELLULOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL HYDROXYPROPYL METHYLCELLULOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL HYDROXYPROPYL METHYLCELLULOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL POLYVINYLPYRROLIDONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL POLYVINYLPYRROLIDONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL POLYVINYLPYRROLIDONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL STARCH & MODIFIED STARCHES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL STARCH & MODIFIED STARCHES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL STARCH & MODIFIED STARCHES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL COATINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL COATINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL COATINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CONTROLLED RELEASE COATINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CONTROLLED RELEASE COATINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CONTROLLED RELEASE COATINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ENTERIC COATINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ENTERIC COATINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ENTERIC COATINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL FILM COATINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL FILM COATINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL FILM COATINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SEAL COATINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SEAL COATINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SEAL COATINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL SUGAR COATINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL SUGAR COATINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL SUGAR COATINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL DILUENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL DILUENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL DILUENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CALCIUM PHOSPHATES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CALCIUM PHOSPHATES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CALCIUM PHOSPHATES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL LACTOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL LACTOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL LACTOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL MICROCRYSTALLINE CELLULOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL MICROCRYSTALLINE CELLULOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL MICROCRYSTALLINE CELLULOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL DISINTEGRANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL DISINTEGRANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL DISINTEGRANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL LUBRICANTS & GLIDANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL LUBRICANTS & GLIDANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL LUBRICANTS & GLIDANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL POLYOLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL POLYOLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL POLYOLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL MANNITOL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL MANNITOL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL MANNITOL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SORBITOL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SORBITOL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL SORBITOL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PRESERVATIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PRESERVATIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL PRESERVATIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SOLUBILIZERS & SURFACTANTS/EMULSIFIERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL SOLUBILIZERS & SURFACTANTS/EMULSIFIERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL SOLUBILIZERS & SURFACTANTS/EMULSIFIERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ESTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ESTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ESTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL POLYSORBATES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL POLYSORBATES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL POLYSORBATES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL TRIGLYCERIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL TRIGLYCERIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL TRIGLYCERIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SUSPENDING & VISCOSITY AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SUSPENDING & VISCOSITY AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SUSPENDING & VISCOSITY AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL NATURAL EXCIPIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL NATURAL EXCIPIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL NATURAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL SYNTHETIC EXCIPIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL SYNTHETIC EXCIPIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL SYNTHETIC EXCIPIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL INJECTABLE FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL INJECTABLE FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL INJECTABLE FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL ORAL FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ORAL FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ORAL FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL POWDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL POWDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL POWDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL TOPICAL FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL TOPICAL FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL TOPICAL FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL CREAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL GELS & OINTMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL GELS & OINTMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL GELS & OINTMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL LOTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL LOTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL LOTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL BIOPHARMACEUTICAL & PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL BIOPHARMACEUTICAL & PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL BIOPHARMACEUTICAL & PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL CONTRACT MANUFACTURERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL CONTRACT MANUFACTURERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL CONTRACT MANUFACTURERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 177. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 178. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 179. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 180. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 181. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 182. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 183. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 184. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 185. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 186. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 187. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 188. EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 192. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 194. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 198. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 199. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 200. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 202. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 203. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 204. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 205. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 206. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 207. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 208. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 209. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 210. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 211. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 212. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 213. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 214. AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 216. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 217. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 218. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 219. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 220. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 221. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 222. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 223. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 224. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 225. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 226. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 227. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 228. ASEAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 230. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 231. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 232. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 233. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 234. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 235. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 236. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 237. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 238. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 239. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 240. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 241. GCC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 256. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 257. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 258. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 259. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 260. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 261. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 262. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 263. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 264. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 265. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 266. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 267. BRICS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 269. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 270. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 271. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 272. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 273. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 274. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 275. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 276. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 277. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 278. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 279. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 280. G7 BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 281. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 282. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 283. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 284. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 285. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 286. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 287. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 288. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 289. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 290. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 291. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 292. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 293. NATO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 294. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 295. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 297. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 298. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 299. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 300. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 301. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 302. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 303. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 304. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 305. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 306. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 307. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 309. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 310. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 311. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 312. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 313. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 314. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 315. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 316. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 317. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 318. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 319. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 320. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 321. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 322. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 323. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 324. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 325. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 326. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 327. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 328. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 329. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 330. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 331. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 332. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 333. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 334. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 335. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 336. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2017-2032 (USD MILLION)
TABLE 337. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2017-2032 (USD MILLION)
TABLE 338. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2017-2032 (USD MILLION)
TABLE 339. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2017-2032 (USD MILLION)
TABLE 340. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2017-2032 (USD MILLION)
TABLE 341. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 342. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 343. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 344. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY

Companies Mentioned

  • ABITEC Corporation
  • Actylis
  • Asahi Kasei Corporation
  • Ashland Inc.
  • Avantor, Inc.
  • BASF SE
  • Clariant International Ltd.
  • Colorcon Ltd.
  • Croda International PLC
  • DFE Pharma GmbH & Co KG
  • Eastman Chemical Company
  • Evonik Industries AG
  • Fuji Chemical Industries Co., Ltd.
  • IMCD N.V.
  • Innophos Holdings, Inc.
  • International Flavors & Fragrances Inc.
  • JRS PHARMA GmbH + Co. KG
  • Kerry Group PLC
  • Meggle Group GmbH
  • Merck KGaA
  • Mitsubishi Chemical Group Corporation
  • NOF Corporation
  • Novo Nordisk A/S
  • Pfanstiehl, Inc.
  • Roquette Frères S.A.
  • Shin-Etsu Chemical Co., Ltd.
  • Sigachi Industries Limited
  • Spectrum Laboratory Products, Inc.
  • SPI Pharma, Inc. By Associated British Foods
  • The Archer-Daniels-Midland Company
  • The Dow Chemical Company
  • The Lubrizol Corporation
  • Wacker Chemie AG

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.25 Billion
Forecasted Market Value ( USD ) by 2032 $ 7.72 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Pharmaceutical Excipient Market - Global Forecast 2026-2032 - Product Image

Pharmaceutical Excipient Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Organic Pharmaceutical Excipients Market - Global Forecast 2026-2032 - Product Image

Organic Pharmaceutical Excipients Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Biopharmaceutical Excipients Market Report 2026 - Product Image

Biopharmaceutical Excipients Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Biopharmaceutical Excipient Manufacturing Market by Scale of Operation, Type of Modality, Type of Excipient, Chemical Components, Company Size, Source of Manufacturing, End User, and Geographical Regions - Trends and Forecast Till 2035 - Product Image

Biopharmaceutical Excipient Manufacturing Market by Scale of Operation, Type of Modality, Type of Excipient, Chemical Components, Company Size, Source of Manufacturing, End User, and Geographical Regions - Trends and Forecast Till 2035

  • Report
  • 207 Pages
  • Global
From
Pharmaceutical Excipients - Global Strategic Business Report - Product Image

Pharmaceutical Excipients - Global Strategic Business Report

  • Report
  • 223 Pages
  • Global
From

About the Biopharma Excipients Market

The biopharmaceutical excipient market is a subset of the drug discovery industry, which focuses on the development of new drugs and therapies. Excipients are inactive ingredients used to formulate drugs, and are essential for the production of safe and effective medicines. They are used to improve the stability, solubility, and bioavailability of active pharmaceutical ingredients. Excipients also help to protect the drug from environmental factors, such as light and moisture. The biopharmaceutical excipient market is driven by the increasing demand for biopharmaceuticals, as well as the need for improved drug delivery systems. The market is also driven by the growing demand for cost-effective and safe drug formulations. Some of the major companies in the biopharmaceutical excipient market include BASF, Evonik Industries, Ashland, Croda International, and Lubrizol Corporation. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.